The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

Arthritis and Rheumatism
P EmeryDANCER Study Group

Abstract

To examine the efficacy and safety of different rituximab doses plus methotrexate (MTX), with or without glucocorticoids, in patients with active rheumatoid arthritis (RA) resistant to disease-modifying antirheumatic drugs (DMARDs), including biologic agents. A total of 465 patients were randomized into 9 treatment groups: 3 rituximab groups (placebo [n = 149], 500 mg [n = 124], or 1,000 mg [n = 192] on days 1 and 15) each also taking either placebo glucocorticoids, intravenous methylprednisolone premedication, or intravenous methylprednisolone premedication plus oral prednisone for 2 weeks. All patients received MTX (10-25 mg/week); no other DMARDs were permitted. Significantly more patients who received 2 500-mg or 2 1,000-mg infusions of rituximab met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at week 24 (55% and 54%, respectively) compared with placebo (28%; P < 0.0001). ACR50 responses were achieved by 33%, 34%, and 13% of patients, respectively (P < 0.001), and ACR70 responses were achieved by 13%, 20%, and 5% of patients (P < 0.05). Changes in the Disease Activity Score in 28 joints (-1.79, -2.05, -0.67; P < 0.0001) and moderate to good responses on the European League Agai...Continue Reading

References

Feb 1, 1980·Arthritis and Rheumatism·J F FriesH R Holman
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Sep 14, 2002·Annals of the Rheumatic Diseases·M J LeandroG Cambridge
May 28, 2004·Scandinavian Journal of Rheumatology·C KneitzH P Tony
Jun 18, 2004·The New England Journal of Medicine·Jonathan C W EdwardsTim Shaw
Jun 23, 2004·Annals of the Rheumatic Diseases·N FelteliusUNKNOWN ARTIS Group
Oct 29, 2004·Rheumatology·J C W Edwards, G Cambridge
Aug 2, 2005·Cancer Treatment Reviews·Eva Kimby
Oct 18, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Heather KrammAlan Bridges

❮ Previous
Next ❯

Citations

Jun 19, 2013·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M VisW F Lems
Nov 26, 2009·European Journal of Clinical Pharmacology·Mao Mao AnYuan Ying Jiang
Dec 17, 2009·Rheumatology International·Joerg Christoph HenesIna Koetter
Feb 18, 2011·Rheumatology International·Martin FeuchtenbergerHans-Peter Tony
Feb 13, 2007·Zeitschrift für Rheumatologie·A Rubbert-Roth
Oct 3, 2008·Zeitschrift für Rheumatologie·A Rubbert-RothUNKNOWN Kommission Pharmakotherapie der DGRh
May 19, 2009·Zeitschrift für Rheumatologie·P Roll, H-P Tony
May 19, 2009·Zeitschrift für Rheumatologie·W A SchmidtD Wernicke
Aug 10, 2010·Zeitschrift für Rheumatologie·E Feist, T Dörner
Aug 13, 2010·Zeitschrift für Rheumatologie·J Wollenhaupt, K Krüger
Nov 11, 2010·Zeitschrift für Rheumatologie·M FeuchtenbergerC Kneitz
Aug 26, 2010·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Arnd HeiligenhausGerhild Wildner
Oct 22, 2008·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Michael Walsh, David Jayne
Dec 2, 2010·Clinical Rheumatology·Annette F JanssonVeit Grote
Nov 30, 2011·Clinical Rheumatology·Richard Charles John CampbellDavid L Scott
Jun 15, 2007·Modern Rheumatology·Yoshiya TanakaTakao Koike
Dec 25, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·J Smolen, D Aletaha
Dec 8, 2009·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Sonja MerkesdalAndrea Rubbert-Roth
Mar 1, 2012·Inflammopharmacology·Anshuman P Malaviya, Andrew J K Ostör
Oct 12, 2012·Current Allergy and Asthma Reports·Jennifer L RogersTeresa K Tarrant
Nov 26, 2010·Current Rheumatology Reports·Robert Woodrick, John Varga
Aug 21, 2013·Current Rheumatology Reports·Elana J Bernstein, Lisa A Mandl
Nov 10, 2007·Clinical Reviews in Allergy & Immunology·Jiska M MeijerCees G M Kallenberg
Feb 14, 2008·Clinical Reviews in Allergy & Immunology·Claudio GalarzaJuan-Manuel Anaya
Jan 9, 2008·Clinical Reviews in Allergy & Immunology·Andreea Coca, Jennifer H Anolik
Jun 22, 2012·Clinical Reviews in Allergy & Immunology·Rita A MouraJoão E Fonseca
Dec 5, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Sabeen Lulu, Emmanuelle Waubant
Dec 4, 2012·Dermatology and Therapy·Labib R ZakkaA Razzaque Ahmed
Jan 1, 2008·Reumatología clinica·José MorenoFrancisco Medina
Aug 26, 2006·Nature Clinical Practice. Rheumatology·Catherine B Driver, Michael H Weisman
Nov 1, 2006·Nature Clinical Practice. Rheumatology·Edward C Keystone
Sep 10, 2008·Nature Clinical Practice. Rheumatology·Anatole Kleiner, R John Looney
Dec 30, 2006·Nature Reviews. Drug Discovery·Vibeke StrandJohn D Isaacs
Mar 29, 2013·Nature Reviews. Drug Discovery·Jean G SathishB Kevin Park
Jul 8, 2009·Nature Reviews. Rheumatology·Thomas DörnerGerd R Burmester
Oct 3, 2009·Nature Reviews. Rheumatology·Ronald F van Vollenhoven
May 5, 2009·Nature Reviews. Rheumatology·Mark C Fisher, Jeffrey D Greenberg
Dec 2, 2010·Nature Reviews. Rheumatology·Jos N HoesJohannes W J Bijlsma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Disease Therapy

In autoimmune diseases, the immune system responds and attacks self-antigens and damages or impairs the function of the tissues. The treatment for autoimmune diseases often involves immunosuppressive agents, but newer treatments are being investigated. Discover the latest research on autoimmune disease therapy here.